| Literature DB >> 35209226 |
Vinusha H Mariwamy1, Shiva Prasad Kollur2,3, Bindya Shivananda1, Muneera Begum1, Chandan Shivamallu4, Chandan Dharmashekara4, Sushma Pradeep4, Anisha S Jain4, Shashanka K Prasad4, Asad Syed5, Abdallah M Elgorban5, Salim Al-Rejaie6, Joaquín Ortega-Castro7, Juan Frau7, Norma Flores-Holguín8, Daniel Glossman-Mitnik8.
Abstract
Researchers are interested in Schiff bases and their metal complexes because they offer a wide range of applications. The chemistry of Schiff bases of heterocompounds has got a lot of attention because of the metal's ability to coordinate with Schiff base ligands. In the current study, a new bidentate Schiff base ligand, N-((1H-pyrrol-2-yl)methylene)-6-methoxypyridin-3-amine (MPM) has been synthesized by condensing 6-methoxypyridine-3-amine with pyrrole-2-carbaldehyde. Further, MPM is used to prepare Cu(II) and Co(II) metal complexes. Analytical and spectroscopic techniques are used for the structural elucidation of the synthesized compounds. Both MPM and its metal complexes were screened against Escherichia coli, Bacillus subtilis, Staphylococcus aureus and Klebsiella pneumoniae species for antimicrobial studies. Furthermore, these compounds were subjected to in silico studies against bacterial proteins to comprehend their best non-bonded interactions. The results confirmed that the Schiff base ligand show considerably higher binding affinity with good hydrogen bonding and hydrophobic interactions against various tested microbial species. These results were complemented with a report of the Conceptual DFT global reactivity descriptors of the studied compounds together with their biological scores and their ADMET computed parameters.Entities:
Keywords: ADMET; Conceptual DFT; Schiff base; antimicrobial activity; biological scores; molecular docking; spectroscopic techniques
Mesh:
Substances:
Year: 2022 PMID: 35209226 PMCID: PMC8880514 DOI: 10.3390/molecules27041436
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of Schiff base ligand, MPM.
Figure 1Proposed structure for the MPM-Co (II) (left) and MPM-Cu (II) (right) complexes.
Physical data of Schiff base ligand and its metal complexes.
| Compound | Molecular Formula | Molecular Mass | Yield | |
|---|---|---|---|---|
| Calculated | Experimental | |||
| MPM | C11H11N3O | 201.22 | 202.09 | 78 |
| MPM-Cu(II) | C22H20CuN6O2 | 464.00 | 463.13 | 69 |
| MPM-Co(II) | C22H20CoN6O2 | 459.39 | 458.26 | 73 |
Figure 2Structures of MPM, MPM-Cu(II) and MPM-Co(II) drawn from ChemSketch software and visualized using Chimera software.
Figure 3Crystal Structures of bacterial proteins: (A) Bacillus subtilis, (B) Staphylococcus aureus, (C) Escherichia coli and (D) Klebsiella pneumoniae.
Figure 4Mass spectrum of MPM.
Figure 5H NMR spectrum of MPM.
Figure 6C NMR spectrum of MPM.
Figure 7IR spectrum of MPM.
Figure 8UV-Visible spectrum of MPM.
Antimicrobial test results showing the diameter of the zone of inhibition in different concentrations of MPM, MPM-Cu(II) and MPM-Co(II) for respective organisms.
| Compound | Concentration | ||||
|---|---|---|---|---|---|
| MPM | 25 | 0.25 | 0.13 | 0.56 | 0.16 |
| 50 | 1.03 | 0.37 | 0.72 | 0.89 | |
| 75 | 1.28 | 0.96 | 1.25 | 1.72 | |
| 100 | 1.03 | 1.74 | 1.80 | 1.86 | |
| MPM-Cu(II) | 25 | 1.74 | 0.20 | 0.18 | 0.11 |
| 50 | 0.41 | 0.25 | 0.92 | 0.68 | |
| 75 | 0.59 | 0.74 | 0.67 | 1.13 | |
| 100 | 0.72 | 0.97 | 1.26 | 1.63 | |
| MPM-Co(II) | 25 | 0.11 | 0.22 | 0.28 | 0.16 |
| 50 | 0.29 | 0.64 | 0.94 | 0.58 | |
| 75 | 0.28 | 1.10 | 0.98 | 1.72 | |
| 100 | 0.76 | 1.45 | 1.58 | 1.86 | |
| Chloramphenicol | 2.40 | 2.54 | 2.85 | 3.14 | |
Figure 9Bacterials growth curve of B. subtilus, S. aureus, E. coli and K. pneumoniae.
Figure 10Citotoxicity effect of the synthesized MPM compound and standard drug Doxorubicin against HepG2 cells for about 24 h using MTT assay at different concentrations ranging from 3.125 to 200 g/mL.
Molecular Docking analysis of synthesized compounds against bacterial proteins (1QD9, 5C2Z, 5I5H and 3O7J).
| SI No. | Bacterial | Compound | Binding Affinity | HB Forming Amino |
|---|---|---|---|---|
| MPM | −5.6 | - | ||
| 1 | 1QD9 | MPM-Cu(II) | −6.6 | GLY-31 |
| MPM-Co(II) | −5.5 | GLU-117, GLY-31 | ||
| MPM | −6.4 | HIS-96 | ||
| 2 | 5C2Z | MPM-Cu(II) | −6.8 | GLY-143, ASP-145 |
| MPM-Co(II) | −7.2 | GLY-142, GLY-145 | ||
| MPM | −7.4 | ASP-268, ASP-347 | ||
| 3 | 5I5H | MPM-Cu(II) | −5.9 | ASN-200 |
| MPM-Co(II) | −6.2 | GLY-142, ASP-145 | ||
| 4 | 3O7J | MPM | −5.4 | GLU-30, VAL-23 |
| ALA-20 | ||||
| MPM-Cu(II) | −6.5 | THR-31, ALA-37 | ||
| MPM-Co(II) | −5.6 | GLN-181 |
Figure 11A bar graph depicting the binding affinity values (Kcal/mol) of each ligand docked to the active site of respective proteins.
Figure 122D representation of the non-bonded interactions between the binding residues of 1QD9 protein with (A) MPM, (B) MPM-Cu(II) and (C) MPM-Co(II).
Figure 132D representation of the non-bonded interactions between the binding residues of 5C2Z protein with (A) MPM, (B) MPM-Cu(II) and (C) MPM-Co(II).
Figure 142D representation of the non-bonded interactions between the binding residues of 5I5H protein with (A) MPM, (B) MPM-Cu(II) and (C) MPM-Co(II).
Figure 152D representation of the non-bonded interactions between the binding residues of 3O7J protein with (A) MPM, (B) MPM-Cu(II) and (C) MPM-Co(II).
Global reactivity descriptors of MPM and its metal complexes: Electronegativity (), Hardness (), Electrophilicity (), EEP (), EAP () and NE () (all in eV).
| Compound |
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| MPM | 3.77 | 3.87 | 1.84 | 5.81 | 2.03 | 7.84 |
| MPM-Co(II) | 3.48 | 1.48 | 4.09 | 10.02 | 6.54 | 16.56 |
| MPM-Cu(II) | 3.89 | 3.52 | 2.15 | 6.47 | 2.58 | 9.05 |
Bioactivity scores of the compounds estimated according to the Molinspiration Cheminformatics software for several drug targets of interest for the process of drug discovery.
| Compound | GPCR | ICM | KI | NCL | PI | EI |
|---|---|---|---|---|---|---|
| MPM | −0.63 | −0.31 | −0.15 | −0.61 | −1.06 | 0.07 |
| MPM-Co(II) | −0.09 | −0.12 | 0.08 | −0.02 | −0.19 | 0.08 |
| MPM-Cu(II) | −0.09 | −0.12 | 0.08 | −0.02 | −0.19 | 0.08 |
Computed ADMET properties of the compounds according to the admetSAR software.
| Ptroperty | Model | MPM | MPM-Co(II) | MPM-Cu(II) |
|---|---|---|---|---|
| Absorption | HIA | + | + | + |
| Caco2 | + | + | + | |
| P-gp Substrate | - | - | - | |
| P-gp Inhibitor | - | - | - | |
| Distribution | BBB | + | + | + |
| CYP450 | ||||
| 2C9 Substrate | - | - | - | |
| 2D6 Substrate | - | - | - | |
| 3A4 Substrate | - | + | + | |
| Metabolism | 1A2 Inhibitor | + | + | + |
| 2C9 Inhibitor | - | + | + | |
| 2D6 Inhibitor | - | - | - | |
| C19 Inhibitor | - | + | + | |
| 3A4 Inhibitor | - | - | ||
| Excretion | OCT2 Inhibitor | - | - | - |
| AMES Toxicity | + | + | + | |
| Carcinogens | - | - | - | |
| Toxicity | HERG Inhibitor | - | - | - |
| T. Pyriformis Toxicity | - | High | High | |
| Acute Oral Toxicity | III | III | III |